Results 251 to 260 of about 170,256 (261)

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

Annals of Oncology, 2018
Sarina Piha-Paul, Aaron Hansen, J -P Delord   +2 more
exaly  

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Annals of Oncology, 2016
Hendrik-Tobias Arkenau, Federico Cappuzzo, Enriqueta Felip   +2 more
exaly  

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of Oncology, 2019
Sherene Loi, David W Cescon, Giuseppe Curigliano   +2 more
exaly  

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of Oncology, 2017
Enriqueta Felip, M-J Ahn, M -J Ahn
exaly  

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

Annals of Oncology
P A Fasching, R Dent, H McArthur
exaly  

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial

Annals of Oncology
Hiroshige Yoshioka, Toshiaki Takahashi, A Calles Blanco   +2 more
exaly  

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Annals of Oncology, 2019
Sherene Loi, Michelino de Laurentiis, David W Cescon   +2 more
exaly  

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

European Journal of Cancer, 2019
Benjamin Besse, Luis Paz-Ares, Santiago Ponce Aix   +2 more
exaly  

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

Annals of Oncology
Georgina V Long, A M Arance, D Kee
exaly  

Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study

Annals of Oncology
D T Le, D Fogelman, B V Jensen
exaly